Abstract 2899: Mitophagy imparts enzalutamide resistance in prostate cancer
Hirak S. Basu(The University of Texas Health Science Center at Houston), George Wilding(The University of Texas MD Anderson Cancer Center), Farideh Mehraein‐Ghomi(University of Wisconsin Carbone Cancer Center), Maryanne Naundorf(University of Wisconsin Carbone Cancer Center), Jamie M. Sperger(University of Wisconsin–Madison), Ashley M. Weichman(University of Wisconsin Carbone Cancer Center), Joshua M. Lang(University of Wisconsin–Madison), Cynthia L. Schrieber(University of Wisconsin Carbone Cancer Center), Dawn R. Church(University of Wisconsin–Madison)
Cited by 1
Related Papers
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors
|Proceedings of the National Academy of Sciences|2003|650
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2023|592
Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
|New England Journal of Medicine|2013|568